{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T03:12:41Z","timestamp":1783912361105,"version":"3.55.0"},"reference-count":18,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003621","name":"National Research Foundation of Korea grant funded by the Ministry of Science and ICT","doi-asserted-by":"publisher","award":["NRF-2018R1C1B5045675"],"award-info":[{"award-number":["NRF-2018R1C1B5045675"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"National Research Foundation of Korea grant funded by the Ministry of Science and ICT","doi-asserted-by":"publisher","award":["NRF-2022R1F1A1074366"],"award-info":[{"award-number":["NRF-2022R1F1A1074366"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by elevated platelet counts and an increased risk of thrombotic events, including ischemic strokes. Materials and Methods: We conducted a retrospective analysis of data from consecutive ischemic stroke patients with ET between March 2014 and February 2023. Results: This case series describes the clinical presentation, radiological features, and management of five patients with ET-associated ischemic strokes, all harboring the JAK2 mutation. The diverse radiological findings suggest that both large and small vessel diseases may be influenced by the prothrombotic state induced by ET. A significant elevation in platelet count was observed to correlate with the emergence of new acute infarctions in some cases. Conclusions: The study highlights combined use of antiplatelet and cytoreductive therapy in preventing secondary stroke events in patients with ET and JAK2 mutations. The heterogeneity of stroke patterns in this population necessitates a comprehensive understanding of the underlying pathophysiological mechanisms and tailored therapeutic approaches.<\/jats:p>","DOI":"10.3390\/medicina59071300","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T08:35:47Z","timestamp":1689323747000},"page":"1300","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Essential Thrombocythemia and Ischemic Stroke: A Case Series of Five JAK2-Positive Patients"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8538-9187","authenticated-orcid":false,"given":"Byong-Kyu","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Dongguk University Gyeongju Hospital, Dongguk University College of Medicine, Gyeongju 38067, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Yoon","family":"Eah","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dongguk University Gyeongju Hospital, Dongguk University College of Medicine, Gyeongju 38067, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6498-6882","authenticated-orcid":false,"given":"Jin-Mo","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dongguk University Gyeongju Hospital, Dongguk University College of Medicine, Gyeongju 38067, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2014.35","article-title":"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-939430","article-title":"Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia","volume":"32","author":"Johansson","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"Mayo clinic patients with myeloproliferative neoplasms: Risk-stratified comparison of survival and outcomes data among disease subgroups","volume":"94","author":"Szuber","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.blre.2016.06.001","article-title":"The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances","volume":"30","author":"Barbui","year":"2016","journal-title":"Blood Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Faculty Opinions recommendation of Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2016","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Research"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/STROKEAHA.111.632547","article-title":"Sex differences in long-term outcomes after stroke: Functional outcomes, handicap, and quality of life","volume":"43","author":"Gall","year":"2012","journal-title":"Stroke"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.12.012","article-title":"Ischemic Stroke with Essential Thrombocythemia: A Case Series","volume":"24","author":"Kato","year":"2015","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jns.2013.10.016","article-title":"Stroke in essential thrombocythemia","volume":"336","author":"Marton","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","article-title":"Improving Survival Trends in Primary Myelofibrosis: An International Study","volume":"30","author":"Cervantes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative Neoplasms: A Contemporary Review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients","volume":"91","author":"Haider","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-017-0041-8","article-title":"Essential thrombocythemia treatment algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rungjirajittranon, T., Owattanapanich, W., Ungprasert, P., Siritanaratkul, N., and Ruchutrakool, T. (2019). A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5387-9"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/7\/1300\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:11:55Z","timestamp":1760127115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/7\/1300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":18,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["medicina59071300"],"URL":"https:\/\/doi.org\/10.3390\/medicina59071300","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}